c-Met-IN-19

• UNSPSC Description:

  c-Met-IN-19 (Compound 21j) is a c-Met inhibitor (IC50: 1.99 nM). c-Met-IN-19 shows cytotoxicity against A549, HT-29, SGC-7901, MDA-MB-231 cells with IC50s of 0.25, 0.36, 0.98, 0.76 μM[1].

• Target Antigen:

  c-Met/HGFR

• Type:

  Reference compound

• Related Pathways:

  Protein Tyrosine Kinase/RTK

• Applications:

  Cancer-Kinase/protease

• Field of Research:

  Cancer

• Assay Protocol:

  https://www.medchemexpress.com/c-met-in-19.html

• Solubility:

  10 mM in DMSO

• Smiles:

  COC1=CC2=C(N=CC=C2OC3=CC=C(NC(CCOC)=NS(=O)(CC4=C(Cl)C=CC=C4Cl)=O)C=C3F)C=C1OCCCN5CCOCC5

• Molecular Weight:

  735.65

• References & Citations:

  [1]Nan X, et al. Design, synthesis and biological evaluation of sulfonylamidines as potent c-Met inhibitors by enhancing hydrophobic interaction. Org Biomol Chem. 2023 Sep 20;21(36):7459-7466.

• Shipping Conditions:

  Room temperature

• Clinical Information:

  No Development Reported